Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: An EORTC Receptor and Biomarker Group collaboration

Oncology Reports

Volumn 14, Issue 1, 2005, Pages 235-239

  Grebenchtchikov, N ^a   Maguire, T M ^b   Riisbro, R ^c   Geurts Moespot, A ^a   O'Donovan, N ^b   Schmitt, M ^e   McGreal, G ^b   McDermott, E ^b   O'Higgins, N ^b   Brunner N ^d   Sweep, C G J ^a   Duffy, M J ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c FINSEN LABORATORY   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Breast cancer; PAI 1; Plasma; Prognosis; Tissue type plasminogen activator; uPA receptor; Urokinase plasminogen activator

Indexed keywords

CELL SURFACE RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS; TISSUE PLASMINOGEN ACTIVATOR; TUMOR MARKER; UROKINASE;

ARTICLE; BLOOD; BREAST TUMOR; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; METABOLISM; PATHOLOGY; PROGNOSIS;

BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; RECEPTORS, CELL SURFACE; TISSUE PLASMINOGEN ACTIVATOR; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 24644505437     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Andreasen PA, Kjoller L, Christensen L, et al: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22, 1997. (Pubitemid 27314632)
2. Duffy MJ: The plasminogen activator system: role in malignancy. Current Pharm Design 10: 39-49, 2004.
3. Schmitt M, Harbeck N, Thomssen C, et al: Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 78: 285-296, 1997. (Pubitemid 27289256)
4. Blasi F and Carmeliet P: uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 3: 932-943, 2002. (Pubitemid 35477371)
5. Aguirre Ghiso JA: Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene 21: 2513-2524, 2002.
6. Sidenius N and Blasi F: The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 22: 205-222, 2003. (Pubitemid 36561058)
7. Blasi F: u-PA and cell migration: urokinase receptor as a ligand for a chemotactic G-protein-coupled receptor. Haemostasis 31 (suppl 1): 59, 2001.
8. Duffy MJ: Urokinase plasminogen activator and its inhibitor PAI-1 as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 48: 1194-1197, 2002.
9. Janicke F, Prechtl A, Thomssen C, et al: For the German Chemo No Study Group. Randomized adjuvant chemotherapy trial in high-risk node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Instit 93: 913-920, 2001. (Pubitemid 32624648)
10. Look M P, van Putten WLJ, Duffy MJ, et al: Pooled analysis of prognostic impact of tumor biological factors uPA and PAI-1 in 8377 breast cancer patients. J Natl Cancer Instit 94: 116-128, 2002. (Pubitemid 34121291)
11. Look M, van Putten W, Duffy M, et al: Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients. Thromb Haemost 90: 538-548, 2003. (Pubitemid 37142426)
12. Harbeck N, Kates RE, Gauger K, et al: Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumorderived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost 91:450-456, 2004. (Pubitemid 38396866)
13. deWitte JH, Sweep CGJ, Klijn JGM, et al: Prognostic value of tissue-type plasminogen activator and its complex with the type-1 inhibitor (PAI-1) in breast cancer. Br J Cancer 80: 286-294, 1999. (Pubitemid 29210120)
14. Sten-Linder M, Seddighzadeh M, Engel G, et al: Prognostic importance of uPA/PAI-1 complex in breast cancer. Anticancer Res 21: 2861-2866, 2002.
15. Manders P, Tjan-Heijnen VCG, Span PN, et al: Predictive impact of urokinase-type plasminogen activator type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer. Cancer Res 64: 659-664, 2004. (Pubitemid 38120907)
16. Pedersen AN, Christensen IJ, Stephens RW, et al: The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival. Cancer Res 60: 6927-6934, 2000. (Pubitemid 32059165)
17. Duggan C, Maguire T, McDermott E, et al: Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 61: 597-600, 1995.
18. Grondahl-Hansen J, Peters HA, van Putten WLJ, et al: Prognostic significance of the receptor for urokinase type plasminogen activator in breast cancer. Clin Cancer Res 1: 1079-1087, 1995.
19. Foekens JA, Peters HA, Look MP et al: The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 60: 636-643, 2000. (Pubitemid 30094561)
20. Duffy MJ, O'Grady P, Devaney D, et al: Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res 48: 1348-1349, 1988. (Pubitemid 18075557)
21. Schmitt M, Janicke F and Graeff H: Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. Blood Coagul Fibrinolysis 1: 695-702, 1990.
22. Foekens J, Look MP, Peters HA et al. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Instit 87: 751-756, 1995.
23. Manders P, Tjan-Heijnen VCG, Span PN, et al: The complex between urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) independently predicts response to first-line endocrine therapy in advanced breast cancer. Thromb Haemost 91: 514-521, 2004. (Pubitemid 38396873)
24. Harbeck N, Kates RE, Look MP et al: Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified highrisk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (N=3424). Cancer Res 62: 4617-4622, 2002.
25. Harbeck N, Kates RE and Schmitt M: Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy in primary breast cancer is greatest when used in combination. J Clin Oncol 20: 1000-1007, 2002. (Pubitemid 34141844)
26. Grebenschikov N, Geurts-Moespot A, de Witte H, et al: A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type (PAI-1) in human breast tumour cytosols. Int J Biol Markers 12: 6-14, 1997. (Pubitemid 27229450)
27. Grebenschikov N, Sweep F, Geurts A, et al: ELISA for complexes of urokinase-type and tissue-type plasminogen activators with their type-1 inhibitor (uPA-PAI-1 and tPA-PAI-1). Int J Biol Markers 81: 598-606, 1999. (Pubitemid 29203059)
28. Riisbro R, Piironen T, Brunner N, et al: Measurement of soluble urokinase plasminogen activator receptor in serum. J Clin Ligand Assay 25: 53-56, 2002. (Pubitemid 34984724)
29. Reilly D, Christensen L, Duch M, et al: Type-1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer 50: 208-214, 1992.
30. Nijziel MR, van Oerle R, Hellenbrand D, et al: The prognostic value of the soluble urokinase-type plasminogen receptor (s-uPAR) in plasma of breast cancer patients with and without metastatic disease. J Thromb Haemost 1: 982-986, 2003.
31. Grondahl-Hansen J, Agerlin N, Munkholm-Larsen P, et al: Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer. J Lab Clin Med 111: 42-51, 1988. (Pubitemid 18082736)
32. Pederson AN, Brunner N, Hoyer-Hansen G, et al: Determination of the complex between urokinase and its type-1 inhibitor in plasma from healthy donors and breast cancer patients. Clin Chem 45: 1206-1213, 1999. (Pubitemid 29424259)
33. Riisbro R, Christensen IJ, Pironen T, et al: Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res 8: 1132-1141, 2002. (Pubitemid 34517650)
34. Grondahl-Hansen J, Bach F and Munkholm-Larsen P: Tissue-type plasminogen activator in plasma from breast cancer patients determined by enzyme-linked immunosorbent assay. Br J Cancer 61: 412-414, 1990. (Pubitemid 20106016)
35. Janicke F, Schmitt M, Pache L, et al: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 195-208, 1993. (Pubitemid 23062819)
36. Janicke F, Pache L, Schmitt M, et al: Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 54: 2527-2530, 1994.
37. Bouchet C, Spyratos F, Martin PM, et al: Prognostic value of urokinase-type plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 69: 398-405, 1994. (Pubitemid 24046572)
38. von Tempelhoff G-F, Heilmann L, Dietrich M, et al: Plasmatic plasminogen activator activity in patients with primary breast cancer. Thrombosis Haemost 77: 600-609, 1997.
39. Nielsen HJ, Pappot H, Christensen IJ, et al: Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. Br Med J 316: 827-828, 1998.
40. Stephens RW, Nielsen HJ, Christensen IJ, et al: Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Instit 91: 869-874, 1999. (Pubitemid 29252303)
41. Sier CFM, Stephens R, Bizik J, et al: The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 58: 1843-1849, 1998. (Pubitemid 28217457)
42. Bunting PS: Screening for prostate cancer with prostate-specific antigen: beware of biases. Clin Chim Acta 315: 71-97, 2002.
43. Zhang Q, Wu Y, Ann DK, et al: Mechanisms of hypoxic regulation of plasminogen activator inhibitor-1 gene expression in keloid fibroblasts. J Invest Dermatol 121: 1005-1012, 2003. (Pubitemid 37430966)
44. von Kanel R, Maly FE, Frey K, et al: Contribution of the type I plasminogen activator inhibitor 4G/5G gene polymorphism to impaired fibrinolysis in vital exhaustion. Ital Heart J 4: 791-796, 2003.
45. Jastrzebska M, Goracy I and Naruszewicz M: Relationships between fibrinogen, plasminogen activator inhibitor-1, and their gene polymorphisms in current smokers with essential hypertension. Thromb Res 110: 339-344, 2003. (Pubitemid 37329836)
46. Song Y, Xu W, Chen Y, et al: The influences of genetic and environmental factors on plasma plasminogen activator inhibitor-1 levels in patients with essential hypertension. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 16: 374-376, 1999.
47. Hong Y, Pedersen NL, Egberg N, et al: Moderate genetic influences on plasma levels of plasminogen activator inhibitor-1 and evidence of genetic and environmental influences shared by plasminogen activator inhibitor-1, triglycerides, and body mass index. Arterioscler Thromb Vasc Biol 17: 2776-2782, 1997. (Pubitemid 28016021)
48. Abe H, Takahara K, Nakashima Y, et al: Effect of low dose aspirin on augmented plasminogen activator inhibitor type 1 activity in patients with permanent pacemakers. Pacing Clin Electrophysiol 17: 146-151, 1994. (Pubitemid 24083625)
49. Sweep CGJ, Geurts-Moespot J, Grebenschikov NI, et al: External quality assessment of trans-European multicentre antigen determination (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer 78: 1434-1441 1998. (Pubitemid 28517539)